展品99.2
阿卡迪亞生物科學公司
合併資產負債表
(未經審計)
(單位:千,共享數據除外)
1
|
|
|
|
|
|
|
||
|
|
2022年9月30日 |
|
|
2021年12月31日 |
|
||
資產 |
|
|
|
|
|
|
||
流動資產: |
|
|
|
|
|
|
||
現金和現金等價物 |
|
$ |
22,719 |
|
|
$ |
28,685 |
|
應收賬款和其他應收賬款,扣除壞賬準備 |
|
|
2,726 |
|
|
|
1,370 |
|
庫存,淨流動 |
|
|
3,342 |
|
|
|
4,433 |
|
持有待售資產 |
|
|
254 |
|
|
|
— |
|
預付費用和其他流動資產 |
|
|
990 |
|
|
|
900 |
|
流動資產總額 |
|
|
30,031 |
|
|
|
35,388 |
|
財產和設備,淨額 |
|
|
848 |
|
|
|
2,291 |
|
使用權資產 |
|
|
2,073 |
|
|
|
3,081 |
|
庫存,非流動淨額 |
|
|
984 |
|
|
|
2,494 |
|
無形資產,淨額 |
|
|
373 |
|
|
|
484 |
|
其他非流動資產 |
|
|
165 |
|
|
|
180 |
|
總資產 |
|
$ |
34,474 |
|
|
$ |
43,918 |
|
負債和股東權益 |
|
|
|
|
|
|
||
流動負債: |
|
|
|
|
|
|
||
應付賬款和應計費用 |
|
$ |
2,748 |
|
|
$ |
3,638 |
|
應付關聯方的款項 |
|
|
47 |
|
|
|
64 |
|
經營租賃負債--流動 |
|
|
986 |
|
|
|
1,074 |
|
其他流動負債 |
|
|
270 |
|
|
|
264 |
|
流動負債總額 |
|
|
4,051 |
|
|
|
5,040 |
|
經營租賃負債--非流動 |
|
|
1,269 |
|
|
|
2,220 |
|
普通股認股權證和期權負債 |
|
|
2,135 |
|
|
|
3,392 |
|
其他非流動負債 |
|
|
2,000 |
|
|
|
2,070 |
|
總負債 |
|
|
9,455 |
|
|
|
12,722 |
|
承付款和或有事項(附註15) |
|
|
|
|
|
|
||
股東權益: |
|
|
|
|
|
|
||
普通股,面值0.001美元-150,000,000股授權為 |
|
|
65 |
|
|
|
63 |
|
額外實收資本 |
|
|
278,618 |
|
|
|
257,515 |
|
累計赤字 |
|
|
(253,615 |
) |
|
|
(226,485 |
) |
股東權益總額 |
|
|
25,068 |
|
|
|
31,093 |
|
非控制性權益 |
|
|
(49 |
) |
|
|
103 |
|
股東權益總額 |
|
|
25,019 |
|
|
|
31,196 |
|
總負債和股東權益 |
|
$ |
34,474 |
|
|
$ |
43,918 |
|
2
阿卡迪亞生物科學公司
合併經營報表和全面虧損
(未經審計)
(以千為單位,不包括共享數據和每股數據)
|
|
截至9月30日的三個月, |
|
|
截至9月30日的9個月, |
|
||||||||||
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
收入: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
產品 |
|
$ |
1,851 |
|
|
$ |
2,324 |
|
|
$ |
7,967 |
|
|
$ |
4,506 |
|
版税 |
|
|
17 |
|
|
|
35 |
|
|
|
117 |
|
|
|
86 |
|
許可證 |
|
|
10 |
|
|
|
17 |
|
|
|
872 |
|
|
|
17 |
|
總收入 |
|
|
1,878 |
|
|
|
2,376 |
|
|
|
8,956 |
|
|
|
4,609 |
|
營業費用(收入): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
收入成本 |
|
|
1,344 |
|
|
|
2,511 |
|
|
|
8,250 |
|
|
|
4,954 |
|
研發 |
|
|
255 |
|
|
|
1,038 |
|
|
|
1,009 |
|
|
|
3,328 |
|
出售Verdeca獲得的收益 |
|
|
— |
|
|
|
— |
|
|
|
(1,138 |
) |
|
|
— |
|
無形資產減值準備 |
|
|
— |
|
|
|
120 |
|
|
|
72 |
|
|
|
120 |
|
或有對價的公允價值變動 |
|
|
— |
|
|
|
— |
|
|
|
(70 |
) |
|
|
(140 |
) |
財產和設備減值 |
|
|
24 |
|
|
|
1,108 |
|
|
|
370 |
|
|
|
1,319 |
|
(收益)出售財產和設備的損失 |
|
|
— |
|
|
|
— |
|
|
|
(386 |
) |
|
|
17 |
|
銷售、一般和行政 |
|
|
4,835 |
|
|
|
6,312 |
|
|
|
13,834 |
|
|
|
16,733 |
|
總運營費用 |
|
|
6,458 |
|
|
|
11,089 |
|
|
|
21,941 |
|
|
|
26,331 |
|
運營虧損 |
|
|
(4,580 |
) |
|
|
(8,713 |
) |
|
|
(12,985 |
) |
|
|
(21,722 |
) |
利息收入(費用) |
|
|
95 |
|
|
|
(15 |
) |
|
|
123 |
|
|
|
(23 |
) |
其他收入(費用),淨額 |
|
|
43 |
|
|
|
(7 |
) |
|
|
13 |
|
|
|
10,214 |
|
普通股認股權證和期權負債的公允價值變動 |
|
|
1,880 |
|
|
|
4,777 |
|
|
|
1,880 |
|
|
|
4,601 |
|
取消購買力平價貸款的收益 |
|
|
— |
|
|
|
1,123 |
|
|
|
— |
|
|
|
1,123 |
|
發行和發行成本 |
|
|
(314 |
) |
|
|
— |
|
|
|
(314 |
) |
|
|
(769 |
) |
所得税前淨虧損 |
|
|
(2,876 |
) |
|
|
(2,835 |
) |
|
|
(11,283 |
) |
|
|
(6,576 |
) |
所得税撥備 |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
(1 |
) |
淨虧損 |
|
|
(2,877 |
) |
|
|
(2,836 |
) |
|
|
(11,284 |
) |
|
|
(6,577 |
) |
非控股權益應佔淨虧損 |
|
|
(10 |
) |
|
|
(661 |
) |
|
|
(152 |
) |
|
|
(1,199 |
) |
普通股股東應佔淨虧損 |
|
$ |
(2,867 |
) |
|
$ |
(2,175 |
) |
|
$ |
(11,132 |
) |
|
$ |
(5,378 |
) |
普通股股東每股淨虧損: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
基本的和稀釋的 |
|
$ |
(0.12 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.48 |
) |
|
$ |
(0.26 |
) |
加權-每股使用的平均股份數 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
基本的和稀釋的 |
|
|
24,552,543 |
|
|
|
22,177,423 |
|
|
|
22,984,816 |
|
|
|
20,976,105 |
|
其他綜合虧損,税後淨額 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
外幣折算調整 |
|
|
— |
|
|
|
(12 |
) |
|
|
— |
|
|
|
(24 |
) |
其他綜合損失 |
|
|
— |
|
|
|
(12 |
) |
|
|
— |
|
|
|
(24 |
) |
普通股股東應佔綜合虧損 |
|
$ |
(2,867 |
) |
|
$ |
(2,187 |
) |
|
$ |
(11,132 |
) |
|
$ |
(5,402 |
) |
3
阿卡迪亞生物科學公司
合併現金流量表
(未經審計)
(單位:千)
|
|
截至9月30日的9個月, |
|
|||||
|
|
|
2022 |
|
|
|
2021 |
|
經營活動的現金流: |
|
|
|
|
|
|
||
淨虧損 |
|
$ |
(11,284 |
) |
|
$ |
(6,577 |
) |
對淨虧損與業務活動中使用的現金進行核對的調整: |
|
|
|
|
|
|
||
普通股認股權證和期權負債的公允價值變動 |
|
|
(1,880 |
) |
|
|
(4,601 |
) |
或有對價的公允價值變動 |
|
|
(70 |
) |
|
|
(140 |
) |
發行和發行成本 |
|
|
314 |
|
|
|
769 |
|
折舊 |
|
|
354 |
|
|
|
737 |
|
無形資產攤銷 |
|
|
39 |
|
|
|
99 |
|
租賃攤銷 |
|
|
686 |
|
|
|
914 |
|
無形資產減值準備 |
|
|
72 |
|
|
|
120 |
|
(收益)處置財產和設備的損失 |
|
|
(386 |
) |
|
|
17 |
|
基於股票的薪酬 |
|
|
897 |
|
|
|
1,035 |
|
壞賬支出 |
|
|
32 |
|
|
|
— |
|
公司證券的已實現收益 |
|
|
— |
|
|
|
(10,222 |
) |
財產和設備減值 |
|
|
370 |
|
|
|
1,319 |
|
存貨減記 |
|
|
1,530 |
|
|
|
1,802 |
|
取消購買力平價貸款的收益 |
|
|
— |
|
|
|
(1,123 |
) |
出售Verdeca獲得的收益 |
|
|
(1,138 |
) |
|
|
— |
|
經營性資產和負債變動情況: |
|
|
— |
|
|
|
— |
|
應收賬款和其他應收賬款 |
|
|
(534 |
) |
|
|
(47 |
) |
盤存 |
|
|
1,071 |
|
|
|
(2,651 |
) |
預付費用和其他流動資產 |
|
|
(90 |
) |
|
|
(452 |
) |
其他非流動資產 |
|
|
15 |
|
|
|
(159 |
) |
應付賬款和應計費用 |
|
|
(890 |
) |
|
|
972 |
|
應付關聯方的款項 |
|
|
(17 |
) |
|
|
(29 |
) |
未賺取收入 |
|
|
— |
|
|
|
(8 |
) |
其他流動負債 |
|
|
6 |
|
|
|
1 |
|
經營租賃負債 |
|
|
(718 |
) |
|
|
(984 |
) |
用於經營活動的現金淨額 |
|
|
(11,621 |
) |
|
|
(19,208 |
) |
投資活動產生的現金流: |
|
|
|
|
|
|
||
出售財產和設備所得收益 |
|
|
897 |
|
|
|
2 |
|
出售Verdeca的收益-已收到收入 |
|
|
285 |
|
|
|
— |
|
購置財產和設備 |
|
|
(46 |
) |
|
|
(919 |
) |
收購,扣除收購現金後的淨額 |
|
|
— |
|
|
|
(4,250 |
) |
銷售收益和投資到期日 |
|
|
— |
|
|
|
21,845 |
|
投資活動提供(用於)的現金淨額 |
|
|
1,136 |
|
|
|
16,678 |
|
融資活動的現金流: |
|
|
|
|
|
|
||
發行普通股、預先出資認股權證及 |
|
|
5,000 |
|
|
|
— |
|
支付與2022年8月發售有關的發售費用 |
|
|
(488 |
) |
|
|
— |
|
發行普通股及認股權證所得收益 |
|
|
— |
|
|
|
25,147 |
|
支付與2021年1月PIPE有關的要約費用 |
|
|
— |
|
|
|
(1,912 |
) |
行使認股權證所得收益 |
|
|
— |
|
|
|
22 |
|
債務本金償付 |
|
|
— |
|
|
|
(2,032 |
) |
ESPP購買收益 |
|
|
7 |
|
|
|
39 |
|
從非控制性權益收到的出資 |
|
|
— |
|
|
|
750 |
|
融資活動提供的現金淨額 |
|
|
4,519 |
|
|
|
22,014 |
|
外幣換算對現金及現金等價物的影響 |
|
|
— |
|
|
|
(1 |
) |
現金及現金等價物淨(減)增 |
|
|
(5,966 |
) |
|
|
19,483 |
|
現金和現金等價物--期初 |
|
|
28,685 |
|
|
|
16,043 |
|
現金和現金等價物--期末 |
|
$ |
22,719 |
|
|
$ |
35,526 |
|
現金流量信息的補充披露: |
|
|
|
|
|
|
||
繳納所得税的現金 |
|
$ |
— |
|
|
$ |
1 |
|
支付利息的現金 |
|
$ |
1 |
|
|
$ |
25 |
|
非現金投資和融資活動: |
|
|
|
|
|
|
||
Arcadia Wellness交易結束時發行的普通股 |
|
$ |
— |
|
|
$ |
2,053 |
|
採用ASU 2020-06後普通股認股權證負債重新分類為權益 |
|
$ |
3,392 |
|
|
$ |
— |
|
向配售代理髮行幷包括在發售中的普通股期權 |
|
$ |
191 |
|
|
$ |
— |
|
發行給配售代理幷包括在發售中的普通權證 |
|
$ |
— |
|
|
$ |
942 |
|
用新的經營租賃負債換取的使用權資產 |
|
$ |
114 |
|
|
$ |
1,662 |
|
在應收賬款和其他應收賬款中出售Verdeca的收益 |
|
$ |
854 |
|
|
$ |
— |
|
# # #
4